0001209191-14-016819.txt : 20140304 0001209191-14-016819.hdr.sgml : 20140304 20140304174248 ACCESSION NUMBER: 0001209191-14-016819 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140303 FILED AS OF DATE: 20140304 DATE AS OF CHANGE: 20140304 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AGIOS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001439222 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 38 SIDNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 617-272-5275 MAIL ADDRESS: STREET 1: 38 SIDNEY STREET STREET 2: 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Higgons John Duncan CENTRAL INDEX KEY: 0001581954 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36014 FILM NUMBER: 14666389 MAIL ADDRESS: STREET 1: C/O AGIOS PHARMACEUTICALS, INC. STREET 2: 38 SIDNEY STREET, 2ND FLOOR CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2014-03-03 0 0001439222 AGIOS PHARMACEUTICALS INC AGIO 0001581954 Higgons John Duncan C/O AGIOS PHARMACEUTICALS, INC. 38 SIDNEY STREET, 2ND FLOOR CAMBRIDGE MA 02139 0 1 0 0 Chief Operating Officer Common Stock 2014-03-03 4 M 0 8000 0.3025 A 117090 D Common Stock 2014-03-03 4 S 0 8000 29.854 D 109090 D Stock Option (right to buy) 0.3025 2014-03-03 4 M 0 8000 0.00 D 2019-08-12 Common Stock 8000 320686 D This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $28.89 to $30.80. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. This option was granted on August 13, 2009. The shares underlying this option vest as to 25% of the shares on May 18, 2010, with the remaining 75% vesting in 36 equal monthly installments thereafter. /s/ Glenn Goddard, as Attorney-in-Fact for John Duncan Higgons 2014-03-04